Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products. The company’s products include home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; and pharmacy automation, software and services. The company’s global footprint and critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision. As of December 31, 2015, the company sold its products in approximately 120 countries. Segments and Products The company operates in two segments: Hospital Products and Renal. The Hospital Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries. The Renal business offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis, in-center hemodialysis (HD), home HD, continuous renal replacement therapy and additional dialysis services. Sales and Distribution The company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. In the United States, third parties, such as Cardinal Health, Inc. warehouse and ship a significant portion of the company’s products through their distribution centers. These centers are generally stocked with adequate inventories to facilitate customer service. Sales and distribution methods include frequent contact by sales and customer service representatives, automated communications via various electronic purchasing systems, circulation of catalogs and merchandising bulletins, direct-mail campaigns, trade publication presence and advertising. International sales are made and products are distributed on a direct basis or through independent distributors or sales agents in approximately 100 countries as of December 31, 2015. International Operations The majority of the company’s revenues are generated outside of the United States and geographic expansion remains a core component of the company’s strategy. The company’s international presence includes operations in Europe (including Eastern and Central Europe), the Middle East, Africa, the Asia-Pacific, Latin America and Canada. Research and Development Expenditures for the company’s research and development activities were $603 million in 2015. Government Regulation The Food and Drug Administration (FDA) in the United States, the European Medicines Agency in Europe, the State Food and Drug Administration in China, and other government agencies inside and outside of the United States, administer requirements covering the testing, safety, effectiveness, manufacturing, labeling, promotion and advertising, distribution and post-market surveillance of the company’s products. In the United States, the company is subject to the oversight of FDA, Office of the Inspector General within the Department of Health and Human Services (OIG), the Center for Medicare/Medicaid Services, the Department of Justice, Environmental Protection Agency, Department of Defense and Customs and Border Protection in addition to others. The company supplies products and services to healthcare providers that are reimbursed by federally funded programs such as Medicare. The company’s activities are subject to regulation by Center for Medicare/Medicaid Services and enforcement by OIG and the Department of Justice. In each jurisdiction outside the United States, the company’s activities are subject to regulation by government agencies including the European Medicines Agency in Europe, the China Food and Drug Administration in China and other agencies in other jurisdictions. History Baxter International Inc. was founded in 1931. The company was incorporated under Delaware law in 1931.
baxter international inc (BAX:New York)
One Baxter Parkway
Deerfield, IL 60015
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for BAX.|
|View Industry Companies|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.